Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN17726268
ISRCTN17726268
Completed
Not Applicable

The efficacy and safety of intra-articular injections with the tumour-necrotising factor alpha (TNFa) antagonist infliximab in patients with chronic or recurrent arthritis of the knee

eiden University Medical Centre (LUMC) (The Netherlands)0 sites40 target enrollmentDecember 19, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsArthritis, spondyloarthropathy, rheumatoid arthritisMusculoskeletal DiseasesOther rheumatoid arthritis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arthritis, spondyloarthropathy, rheumatoid arthritis
Sponsor
eiden University Medical Centre (LUMC) (The Netherlands)
Enrollment
40
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 19, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
eiden University Medical Centre (LUMC) (The Netherlands)

Eligibility Criteria

Inclusion Criteria

  • •1\. Inflammatory arthritis involving a knee (rheumatoid arthritis, juvenile chronic arthritis, spondylarthropathies and arthritis of unknown origin)
  • •2\. Aged above 18 years
  • •3\. Written informed consent
  • •4\. At least two therapeutic corticosteroid injections in the affected joint within a period of one year

Exclusion Criteria

  • •1\. Haemorrhagic disease
  • •2\. Arthritis due to infection, gout or osteoarthritis
  • •3\. Participation in any other study which interferes with or is influenced by this study
  • •4\. Use of oral prednisone in excess of 10 mg/day
  • •5\. Recent change of disease modifying anti\-inflammatory drug (DMARD) therapy (six weeks or less)
  • •6\. Intra\-articular injection with corticosteroid less than two months ago (concerning all joints)
  • •7\. Hypersensitivity to methylprednisolone/triamcinolone, lidocain or infliximab (murine proteins) or intravenous (iv) contrast
  • •8\. Active/latent tuberculosis
  • •9\. Acute/chronic infection
  • •10\. Multiple sclerosis

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Safety and efficacy of intra-articular injections of platelet-rich plasma for the treatment of osteoarthritis of the knee in the Japanese populatioOsteoarthritis of the knee
JPRN-UMIN000011829niversity of Tsukuba Hospital10
Recruiting
Not Applicable
The efficacy and safety of intra-articular injections with the TNF-a antagonist infliximab in patients with chronic or recurrent arthritis of the knee.recurrent or persistent inflammatory arthritis involving a knee (rheumatoid arthritis, juvenile chronic arthritis, spondylarthropathies and arthritis of unknown origin) despite corticosteroid injections intra-articular
NL-OMON24235department of rheumatologyLeids Universitair Medisch CentrumPostbus 9600 RC Leiden40
Recruiting
Phase 2
The effectiveness of Hyaluronic acid/Chondroitin injection on knee performance after surgical fixation.
IRCT20170608034390N13Shahid Beheshti University of Medical Sciences32
Active, not recruiting
Phase 1
Efficacy and safety of 3 intra-articular injections of 500 µg icatibant in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis, continued by an observation of safety and tolerability over a further double-blind 13-week period - NApatients with painful OA in the knee
EUCTR2006-005946-35-SKsanofi-aventis recherche & développement450
Completed
Not Applicable
Safety and performance of the intra-articular injection of animal-free chitosan biomaterial (viscosupplementation) in patients with symptomatic knee osteoarthritis: a pre-market studyArtrosisOsteoarthritis10023213
NL-OMON48771KiOmed PHARMA SA35